CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that enrollment is continuing in its ongoing global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). Specifically, the company is reporting that it has enrolled the first patient in Spain. As part of the trial, the company has opened 37 of 59 planned clinical trial sites; the sites are located in the United States, Italy, France, Spain and Switzerland. The company noted that it plans an interim analysis of the study when 30-50% of participants reach the primary endpoint; the company anticipates that happening later this year. This review will evaluate safety as well as secondary efficacy endpoints, and enrollment will not stop during the analysis. An anthracycline, Berubicin is in a class of anticancer agents that are among the most powerful chemotherapy drugs that have proven to be effective against more types of cancer than any other class of chemotherapeutic agents. “We continue to rapidly build momentum with patient enrollment across our clinical trial sites in Europe,” said CNS Pharmaceuticals CEO John Climaco in the press release. “The pace at which we are enrolling patients is encouraging and driving us toward our planned interim analysis, which we expect mid-year 2023. We sincerely appreciate the institutions, clinicians and staff that are contributing to the conduct of this trial, and are extremely grateful to the patients that choose to participate. We are laser focused on executing on clinical development plans and look forward to providing updates.”
To view the full press release, visit https://ibn.fm/Ck8ka
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme, an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.